lung cancer
Bristol-Myers Squibb launches Opdivo in the UK for lung cancer
August 12, 2015Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo
The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
AstraZeneca receives US approval for Iressa
July 16, 2015Medical Communications, Sales and Marketing AstraZeneca, FDA, Iressa, lung cancer, non-small cell lung cancer
AstraZeneca’s lung cancer therapy Iressa has been approved by the FDA – four years after the company pulled it from the …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
German court rules against Lilly in Alimta patent case
March 10, 2015Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed
A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …
BMS’ Opdivo wins US lung cancer race
March 5, 2015Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo
The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …
Takeda trial hits late-stage buffers
February 17, 2015Research and Development, Sales and Marketing AMG 706, Japan, NSCLC, Takeda, lung cancer, motesanib
Takeda is to scrap an advanced trial of an investigational drug after it failed to show any benefit in survival …
‘Postcode lottery’ still cause of many lung cancer deaths
December 3, 2014Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1
Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
Boehringer’s lung cancer drug gets EMA nod
September 29, 2014Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib
The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …
Genome-driven lung cancer trial launches
June 18, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Genentech, MedImmune, Pfizer, genome, lung cancer
Amgen, Genentech, Pfizer, AstraZeneca and MedImmune – AstraZeneca’s global biologics R&D arm – have each put investigative treatments into a …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
Giotrif increases lung cancer survival
May 16, 2014Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer
Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …
AstraZeneca lung cancer data reveals promise
May 15, 2014Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer
AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …
AstraZeneca begins lung cancer trial
May 9, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer
AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
